VolitionRx Files Two Patent Applications.
NAMUR, Belgium, April 4, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.
"The use of Nucleosomicsin the expanding field of personalized cancer medicine is a new early stage development for us but represents an exciting prospect with the potential for real patient benefit," said Jake Micallef, Chief Scientific Officer of Belgian Volition.
VolitionRx already holds patent applications worldwide for a number of methods of detecting nucleosomes and nucleosome structures; both in-licensed and self-authored.
"These two patents complement our existing Nucleosomics IP, providing us with greater intellectual property protection for our NuQ® products," said Cameron Reynolds, CEO of VolitionRx. "While we work towards applying for regulatory approval for our clinical products in both Europe and the US, we continue to carry out research and development in our Belgian laboratory, expanding our intellectual property base and our understanding of the possibilities – both in diagnostics and therapy monitoring – for our Nucleosomics technology."
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.
VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited